ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 570,20
-0,77%
Dow Jones
38 834,86
0,15%
DAX
18 067,91
-0,31%
Brent Oil
84,695
-0,11%
Bitcoin
64 832,62
-0,47%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Revolution Medicines Inc (RVMD)

  7. Revolution Medicines Inc (RVMD) Actualités

RVMD

Revolution Medicines (RVMD)

Revolution Medicines Inc
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:RVMD
DateHeureSourceTitreSymboleSociété
05/06/202422h05GlobeNewswire Inc.Revolution Medicines to Participate in Goldman Sachs 45th Annual Global Healthcare ConferenceNASDAQ:RVMDRevolution Medicines Inc
08/05/202422h02GlobeNewswire Inc.Revolution Medicines Reports First Quarter 2024 Financial Results and Update on Corporate ProgressNASDAQ:RVMDRevolution Medicines Inc
01/05/202422h05GlobeNewswire Inc.Revolution Medicines to Report Financial Results for First Quarter 2024 After Market Close on May 8, 2024NASDAQ:RVMDRevolution Medicines Inc
09/04/202421h34GlobeNewswire Inc.Revolution Medicines Announces Publication on the Discovery of and Translational Research for RMC-6236, an Investigational RAS(ON) Multi-Selective Tri-Complex Inhibitor Designed to Block Full Spectrum of Oncogenic RAS(ON) ProteinsNASDAQ:RVMDRevolution Medicines Inc
08/04/202417h36GlobeNewswire Inc.Revolution Medicines Announces Publications on the Discovery and Preclinical Profile of Representative of a New Class of RAS(ON) Multi-Selective Inhibitors Designed to Block Full Spectrum of Oncogenic RAS(ON) ProteinsNASDAQ:RVMDRevolution Medicines Inc
04/04/202422h05GlobeNewswire Inc.Revolution Medicines to Participate in Upcoming Investor ConferencesNASDAQ:RVMDRevolution Medicines Inc
28/03/202421h05GlobeNewswire Inc.Revolution Medicines to Deliver Multiple Presentations at the Upcoming American Association for Cancer Research Annual Meeting 2024NASDAQ:RVMDRevolution Medicines Inc
05/03/202422h54Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:RVMDRevolution Medicines Inc
04/03/202423h23Edgar (US Regulatory)Form S-3ASR - Automatic shelf registration statement of securities of well-known seasoned issuersNASDAQ:RVMDRevolution Medicines Inc
26/02/202423h04Edgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:RVMDRevolution Medicines Inc
26/02/202422h05GlobeNewswire Inc.Revolution Medicines Reports Fourth Quarter and Full Year 2023 Financial Results and Update on Corporate ProgressNASDAQ:RVMDRevolution Medicines Inc
26/02/202422h04Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:RVMDRevolution Medicines Inc
20/02/202422h05GlobeNewswire Inc.Revolution Medicines to Report Financial Results for Fourth Quarter and Full Year 2023 After Market Close on February 26, 2024NASDAQ:RVMDRevolution Medicines Inc
09/02/202423h22Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:RVMDRevolution Medicines Inc
22/01/202422h18Edgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:RVMDRevolution Medicines Inc
04/01/202413h00GlobeNewswire Inc.Revolution Medicines to Present at 42nd Annual J.P. Morgan Healthcare ConferenceNASDAQ:RVMDRevolution Medicines Inc
16/11/202320h58Edgar (US Regulatory)Form CERT - Certification by an exchange approving securities for listingNASDAQ:RVMDRevolution Medicines Inc
15/11/202322h04Edgar (US Regulatory)Form 8-A12B - Registration of securities [Section 12(b)]NASDAQ:RVMDRevolution Medicines Inc
15/11/202302h13Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:RVMDRevolution Medicines Inc
09/11/202315h10GlobeNewswire Inc.Revolution Medicines Completes Acquisition of EQRxNASDAQ:RVMDRevolution Medicines Inc
08/11/202317h30GlobeNewswire Inc.Revolution Medicines and EQRx Stockholders Approve EQRx AcquisitionNASDAQ:RVMDRevolution Medicines Inc
06/11/202322h09Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:RVMDRevolution Medicines Inc
06/11/202322h05GlobeNewswire Inc.Revolution Medicines Reports Third Quarter 2023 Financial Results and Update on Corporate ProgressNASDAQ:RVMDRevolution Medicines Inc
01/11/202312h15Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:RVMDRevolution Medicines Inc
01/11/202312h11Edgar (US Regulatory)Form 425 - Prospectuses and communications, business combinationsNASDAQ:RVMDRevolution Medicines Inc
01/11/202312h00GlobeNewswire Inc.Leading Independent Proxy Advisory Firms ISS and Glass Lewis Recommend Revolution Medicines Stockholders Vote “FOR” Proposed Acquisition of EQRx, Inc.NASDAQ:RVMDRevolution Medicines Inc
31/10/202321h15GlobeNewswire Inc.Revolution Medicines to Report Financial Results for Third Quarter 2023 After Market Close on November 6, 2023NASDAQ:RVMDRevolution Medicines Inc
22/10/202308h30GlobeNewswire Inc.Revolution Medicines Presents Promising Clinical Activity and Safety Data from Phase 1/1b Trial of RMC-6236NASDAQ:RVMDRevolution Medicines Inc
13/10/202317h50GlobeNewswire Inc.Revolution Medicines Presents Encouraging Clinical Data for RMC-6236 and RMC-6291 at 2023 Triple MeetingNASDAQ:RVMDRevolution Medicines Inc
04/10/202322h05GlobeNewswire Inc.Revolution Medicines to Present New Clinical Data at Major Oncology Conferences and Host Investor WebcastNASDAQ:RVMDRevolution Medicines Inc
 Showing the most relevant articles for your search:NASDAQ:RVMD

Dernières Valeurs Consultées

LBNK
IGSCUSDT
IGSECoin
USOTC
SBDG
Small Business Development (PK)
EU
BEB157591129
Belfius Bank SA 2.4% Con...
UNSW3
GVTUSDT
Genesis Vision
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés